RCS - Ondine Biomedical - New Independent Study Supports Photodisinfection

Ondine BiomedicalAnnouncement

13/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260113:nRSM6001Oa&default-theme=true

RNS Number : 6001O  Ondine Biomedical Inc.  13 January 2026

13 January 2026

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

New Independent Study Supports Photodisinfection

Ondine Biomedical Provides Biological Context for Nasal Decolonization
Strategies Following Landmark Nasal Microbiome Study

Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial
therapies, highlights new biological evidence supporting its photodisinfection
technology in a newly published study in Nature Communications (Aggarwal et
al., 2025). The research titled "Large-scale characterisation of the nasal
microbiome redefines Staphylococcus aureus colonisation status"   maps the
nasal microbiome in detail and helps explain why conventional screening and
traditional antibiotic based nasal decolonisation treatments have important
clinical limitations.

The multicenter CARRIAGE study analyzed the nasal microbiomes of approximately
1,180 healthy adults and identified seven distinct Community State Types
(CSTs). A primary finding of the study is that Staphylococcus aureus (S.
aureus) colonization-a leading cause of hospital-acquired infections (HAIs)-is
characterized by a low-diversity microbial state (CST-1) that actively
inhibits "Good Neighbor" commensal bacteria.

The research redefined the biological understanding of "intermittent"
carriers. Previously considered a distinct group, these individuals were shown
to be persistent carriers with fluctuating bacterial loads. This finding
suggests that traditional single-point-in-time culture swabs may be an
unreliable metric for risk stratification, as they often fail to detect
pathogens in patients with transiently low microbial levels at the time of
screening.

Emeritus Professor of Microbiology at University College London, Michael
Wilson, stated:

"The CARRIAGE study provides biological context for the limitations of
selective screening. By demonstrating that S. aureus colonization is a stable
community state that can fluctuate in density, the research highlights the
potential value of proactive, broad spectrum universal decolonization
strategies. Photodisinfection was developed to address these biological
challenges by providing a rapid, non-antibiotic method to eliminate a broad
spectrum of pathogens across the adult patient population."

While many hospitals utilize the topical antibiotic mupirocin for
decolonization, the CARRIAGE study identifies specific beneficial bacteria,
such as Corynebacterium species and Dolosigranulum pigrum, that naturally
inhibit S. aureus. Conventional antibiotics can result in prolonged dysbiosis
(microbial imbalance) affecting these beneficial microbes. In contrast,
photodisinfection utilizes a brief oxidative burst to eliminate pathogens.
This physical mode of action does not exert the selection pressure associated
with chemical antibiotics and may facilitate a "microbiome reset," allowing
protective species to repopulate the nasal passage more effectively.

Healthcare workers frequently act as transient vectors for S. aureus. As a
rapid and repeatable tool, photodisinfection may serve as an adjunct to
traditional personal protective equipment (PPE), potentially reducing
transmission without the resistance risks associated with topical
pharmaceuticals.

Carolyn Cross, CEO of Ondine Biomedical:

"The CARRIAGE study provides further evidence that we need to move beyond
selective screening toward universal, effective nasal decolonization.
Steriwave was designed precisely for this purpose: to safely and rapidly
eliminate pathogens in the nasal passages-a major source of infection-without
contributing to antibiotic resistance."

Separate clinical evaluations and health economic modeling presented at the
2025 International Conference on Prevention & Infection Control (ICPIC)
have reported up to a 70% reduction in surgical site infections (SSIs) in
facilities utilizing universal photodisinfection protocols. These evaluations
suggest that the approach can lead to significant cost savings per procedure
by reducing hospital readmissions and length of stay.

Photodisinfection technology is currently deployed in hospitals across Canada
and within the UK's National Health Service (NHS). In the United States, the
technology is advancing through a Phase 3 clinical trial as part of the FDA
regulatory process. Ondine Biomedical remains focused on expanding the
application of photodisinfection into intensive care units, dialysis centers,
oncology, and long-term care facilities to support global antimicrobial
stewardship goals.

 

Enquiries:

 Ondine Biomedical Inc.                                www.ondinebio.com (http://www.ondinebio.com/)
 Carolyn Cross, CEO                                    +1 604 669 0555

or via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                         +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                         +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                      +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

 

About the CARRIAGE Study

The CARRIAGE study analysed the nasal microbiomes of 1,180 healthy adults in
England to better understand S. aureus colonisation-a major risk factor for
infection. Researchers identified distinct microbial community types and
showed that so-called "intermittent carriers" are not a separate group but
reflect fluctuating pathogen levels. The findings explain why traditional
screening can miss at-risk individuals.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAXLLLFQFLFBBB



            Copyright 2019 Regulatory News Service, all rights reserved